2016/2/22 Monday < HBV Day >

	Room 1BC	Room 1A	Room 1D	Room 2	Room 3	Room 4	Room 5	Room 6	Room 7	Room 8	2F
07:40 - 08:40		Morning Symposium (Ajinomoto)	Morning Symposium (Abbott)								
08:45 - 08:50	**Presidential Lecture (Moderator: J.D. Jia)** Osamu Yokosuka										
08:55 - 09:40	**Presidential Plenary (Moderators: O. Yokosuka, L.A. Lesmana, J. Sollano)** *PL-1. LDV/SOF+RBV in HCV Patients with Decompensated Cirrhosis or Liver Transplantation: SOLAR-1+2* Edward Gane(10735)	**Session 1 (Moderators: A. Deepack, C. Lesmana, Y. Ueno)** **HBV Treatment in Various Countries 1** *GS1-1. Nucleotide or IFN for the Treatment of HBV, (Prevention of HCC)* Deepak Amarapurkar	**Session 2 (Moderators: B.C. Yoo, M. Sharma, H. Gazinian)** *Significance of HBV Markers for Clinical Use GS2-1. Pre-S Mutations of HBV and Hepatic Carcinogenesis* Byung-Chul Yoo	**Session 3 (Moderators: M. Mahtab, R. Mareas, S. Mochida)** **Recent Progress in ALF** *GS3-1. ALF in ASIA* Satoshi Mochida	HCV 10331 O-1	HBV 10763 O-88	HCV 10121 O-22	HBV 10615 O-108	HCV 20107 LBO-24	ACLF WS	
09:05 - 09:15	*PL-2 Sofosbuvir/Velpatasvir For The Treatment Of HCV Decompensated Liver Disease Patients: ASTRAL-4 Study* Michael Charlton (10737)				HCV 10844 O-2	HBV 10680 O-89	HCV 10132 O-23	HBV 10809 O-109	HCV 20082 LBO-25		
09:20 - 09:30	*PL-3 Serum HBV-RNA Levels Decline Significantly in Chronic Hepatitis B Patients Dosed with REP2139-CA* Hendrik W. Reesink (10482)	*GS1-2. Clinical Profiles and Treatment Options of Chronic Hepatitis B in Real-life Settings* Jinlin Hou	*GS2-2. Approach for HBV Treatment* Manoj Sharma	*GS3-2. ALF in EU* Richard Moreau	HCV 10484 O-3	HBV 11111 O-90	HCV 10285 O-24	HBV 10176 O-110	HCV 20061 LBO-26		
09:35 - 09:45	*PL-4192 Weeks Tenofovir Disoproxil Fumarate Monotherapy in Chinese Patients with Chronic Hepatitis B* Jinlin Hou (10365)				HCV 11100 O-4	HBV 10780 O-91	HCV 10692 O-25	HBV 11263 O-111	HCV 20155 LBO-27		
09:50 - 10:25	*PL-5 Hepatocellular Carcinoma: Treatment Juntendo University Radiofrequency Ablation (RFA) Training Program* Shuichiro Shiina (11141)	*GS1-3. HBV Treatment in Japan* Yoshiyuki Ueno	*GS2-3. Cellular Hepatic Immunology* Tatsuya Kanto	*GS3-3. Artificial Liver Support of ALF* Kazuaki Inoue	HCV 11125 O-5	HBV 10221 O-92	HCV 10725 O-26	HBV 10360 O-112	HCV 20122 LBO-28		
	PL-6 Acute on Chronic Liver Failure AARC-ACLF Score Predicts 30 Day Survival better than CLIF-SOFA and MELD Scores in Patients with ACLF				HCV 10670 O-6	HBV 10260 O-93	HCV 10727 O-27	HBV 10467 O-113	HCV 20111 LBO-29		
10:00 - 10:35		*GS1-4. HBV Treatment in Philippines* Ian Homer Cua			HCV 11097 O-7	HBV 10628 O-94	HCV 10877 O-28	HBV 10085 O-114			
10:40 - 11:00	Coffee Break				HCV 11072 O-8	HBV 10693 O-95	HCV 11034 O-29	HBV 11248 O-115			
11:05 - 11:20					HCV 10729 O-9	HBV 10577 O-96	HCV 10805 O-72				
11:25 - 11:40					HCV 10726 O-10	HBV 10961 O-97					
11:45 - 12:00	**Lecture 1 (Moderator: D.J. Suh)** *Hepatitis B Treatment* Anna S. Lok	**Session 1 (Moderators: H. Ozkan, A. Chutaputti, I. Cua)** **HBV Treatment in Various Countries 2** *GS1-5. HBV Treatment in Thailand* Anuchit Chutaputti	**Session 4 (Moderators: A. Thompson, R. Gish, T. Kanto)** **Treatment Towards HBsAg Clearance** *GS4-1. New Insight of HBsAg Seroclearance* Jun Cheng	Transplantation 10324 O-190			HCV 10667 O-36	HBV 10225 O-116	Immune 11347 O-83		
12:05 - 12:20				Transplantation 10690 O-191	HCV 10868 O-11	HBV 11307 O-98	HCV 10736 O-31	HBV 10875 O-117	Immune 11272 O-84		
12:25 - 12:40	**Lecture 2 (Moderator: J.H. Kao)** *Hepatitis B in EU* Patrick Marcellin	*GS1-6. HBV Treatment in Indonesia* Laurentius A. Lesmana	*GS4-2. New Endpoints in HBV Drug Development* Robert G. Gish	Transplantation 10653 O-192	HCV 10740 O-12	HBV 10506 O-99	HCV 10538 O-32	HBV 10418 O-118	Immune 10612 O-85		
12:45 - 13:00				Transplantation 10683 O-193	HCV 10941 O-13	HBV 10828 O-100	HCV 11099 O-33	HBV 10715 O-119	Immune 11003 O-86		
13:05 - 13:20	**Lecture 3 (Moderator: A.K. Dokmeci)** *Serum HBsAg and AFP Levels during Acute Hepatitis Flare of Chronic Hepatitis B: A New Look in the Natural Course and Antiviral Therapy* Yun Fan Liaw	*GS1-7. HBV Treatment in Turkey* Hasan Ozkan	*GS4-3. "Curing HBV-New Therapeutic Approaches"* Alexander Thompson	Transplantation 10694 O-194	HCV 10517 O-14	HBV 10799 O-101	HCV 10886 O-34	HBV 10935 O-120	Immune 10970 O-87		
13:25 - 13:40				Transplantation 11324 O-195	HCV 10525 O-15	HBV 10490 O-102	HCV 10580 O-35	HBV 11169 O-121			
13:45 - 14:00							HCV 10915 O-30	HBV 11212 O-122			
14:05 - 14:20	Luncheon Symposium (Abbvie)	Luncheon Symposium (BMS)	Luncheon Symposium (Gilead)								
14:25 - 14:40											
14:45 - 15:00											
15:05 - 15:20											
15:25 - 15:40											
15:45 - 16:00											
16:05 - 16:20											
16:25 - 16:40											
16:45 - 17:00											
17:05 - 17:20											
17:25 - 17:40											
17:40-19:00	Poster Session										Poster Viewing
13:30 - 13:45	**Symposium 6 (Moderators: F.S. Wang , A. Lok, M. Mizokami)** **Novel Therapeutic Strategies for HBV** *S6-1. Chimeric Animal Model*	**Session 1 (Moderators: O. Baatakun, S. Rahman, S. Hamid)** **HBV Treatment in Various Countries 3** *GS1-8. HBV Treatment in Korea* Jung Il Lee	**Session 5 (Moderators: P. Marcellin, C.M. Kim, T. Kanda)** **Basis for Hepatitis Treatment** *GS5-1. Various Hepatitis in Japan* Hiroshi Yatsuhashi	**ACLF Working Party MTG** *DILI / ALF* Harshad Devarbhavi	Transplantation 11000 O-196	HBV 11066 O-103	HCV 11142 O-37	HBV 11200 O-123	Basic 11007 O-207		
13:50 - 14:05	*S6-2. Curing Chronic Hepatitis B Depends on the Restoration of Integrative Immunity against HBV* Fu-Sheng Wang	*GS1-9. HBV Treatment in Pakistan* Shahab Abid	*GS5-2. HAV and HEV* Shigeo Nagashima	*Sepsis / ACLF* Ashok Choudhury	Transplantation 10466 O-197	HBV 10981 O-104	HCV 10672 O-38	HBV 11288 O-124	Basic 11041 O-208		
14:10 - 14:25	*S6-3. Innate Immunity in Hepatitis B* Stephen Locarnini	*GS1-10. HBV Treatment in Mongolia* Oidov Baatarkuu	*GS5-3. Treatment of HDV* Saeed Hamid	*Hepatic Encephalopathy* R K Dhiman	Transplantation 10223 O-198	HBV 10810 O-105	HCV 10523 O-39	HBV 11174 O-125	Basic 10195 O-209		
14:30 - 14:45	*S6-4. HLA and HBV Infection* Masashi Mizokami	*GS1-11. HBV Treatment in Bangladesh* Salimur Rahman	*GS5-4. Androgen Receptor and Hepatitis Virus* Tatsuo Kanda	*Acute Kidney Injury* Rakhi Maiwall	HCV 10724 O-16	HBV 10579 O-106	HCV 10673 O-40	HBV 11339 O-126	Basic 11011 O-210		
14:50 - 15:05	**Symposium 7 (Moderators: J.D. Jia, J.H. Kao, F. Imazeki)** **Treatment of HBV for a Cure** *S7-1. Conventional Treatment* Jidong Jia	*GS1-12. HBV Treatment in Egypt* Gamal Shiha	*GS5-5. Expression of mRNA in Hepatitis B and C* Masao Honda	*Portal Hypertension* Shahab Abid	HCV 10731 O-17	HBV 10989 O-107	HCV 11252 O-41	HBV 10542 O-127	Basic 11362 O-211		
15:10 - 15:25	*S7-2. Nucleotide* George Lau	*GS1-13. HBV Treatment in USA: AASLD Guidelines 2015 and beyond* Robert G. Gish	*GS5-6. Treatment of HEV* Zaigham Abbas	*Artificial Liver Support* Richard Moreau	HCV 10739 O-18	HBV 20003 LBO-7	HCV 10387 O-42	HBV 11344 O-128	Basic 10083 O-212		
15:30 - 15:45					HCV 10971 O-19	HBV 20116 LBO-8	HCV 10684 O-43	HBV 10478 O-129	Basic 10237 O-213		
15:50 - 16:05					HCV 10312 O-20	HBV 20171 LBO-9	HCV 10882 O-44	HBV 11090 O-130	Basic 10325 O-214		
16:10 - 16:25					HCV 11231 O-21	HBV 20071 LBO-10	HCV 11063 O-45	HCC 10382 O-141	Basic 10428 O-215		
16:30 - 16:45					HCV 20157 LBO-1	HBV 20110 LBO-11	HCV 10676 O-46	HCC 11171 O-142	Basic 11254 O-216		
16:50 - 17:05					HCV 20160 LBO-2	HBV 20096 LBO-12	HCV 10903 O-47	HCC 11175 O-143	Basic 11110 O-217		
17:10 - 17:25							HCV 10273 O-48	HCC 10069 O-144	Basic 11281 O-218		
17:30 - 17:45	Coffee Break							HCC 10578 O-145	Basic 11178 O-219		
17:50 - 18:05							HCV 10084 O-49	HCC 10011 O-146			
18:10 - 18:25	*S7-3. Hepatitis B Towards Cure of Virus and Liver Disease* Jia-Horng Kao	**Symposium 8 (Moderators: F. Hollinger, M.F. Yuen, Y. Tanaka)** **Reactivation and Occult Infection of HBV** *S8-1. Coinfection with HIV* Marion Peters	**Session 6 (Moderators: J. George, T. Wakita, N. Kato)** **Nobel Approach for Viral Research** *GS6-1. Micro RNA and HCV* Takasuke Fukuhara		HCV 20161 LBO-3	HCC 20002 LBO-13	HCV 11031 O-50	HCC 10406 O-147	Drug 10792 O-271	AC LF WS	
18:30 - 18:45					HCV 20124 LBO-4	HCC 20131 LBO-14	HCV 10827 O-51	HCC 10279 O-148	Drug 10679 O-272		
18:50 - 19:05	*S7-4. Clinical Cure of Chronic Hepatitis B: Dream or Reality* Fumitaka Suzuki	*S8-2. HBV Reactivation (Insight of Integration)* Yasuhito Tanaka	*GS6-2. GWAS* Koichi Matsuda		HCV 20158 LBO-5	HCC 20132 LBO-15	HCV 10547 O-52		Drug 11250 O-273		
19:10 - 19:25					HCV 20159 LBO-6	HCC 20052 LBO-16	HCV 11098 O-53	HCC 10252 O-149	Drug 20009 LBO-36		
19:30 - 19:45	*S7-5. Interferon Sequencing Therapy of HBV* Qin Ning	*S8-3. Clinical Implication of Occult Hepatitis B* Man-Fung Yuen	*GS6-3. HBV/HCC MICA* Naoya Kato		Pediatric 11192 O-274	HCC 20075 LBO-17	HCV 10355 O-54	HCC 10258 O-150	HBV 20062 LBO-30		
19:50 - 20:05					Pediatric 10479 O-275	HCC 20142 LBO-22	HCV 11260 O-55	HCC 10513 O-151	HBV 20053 LBO-31		
20:10 - 20:25	*S7-6. Update in Immunomodulator Therapy of Chronic Hepatitis B* Teerha Piratvisuth	*S8-4. Occult HBV* F. Blaine Hollinger	*GS6-4. HCV Biology in the Future* Takaji Wakita		Pediatric 10106 O-276	Cirrhosis 20001 LBO-18	HCV 10910 O-56	HCC 11244 O-152	HCC 20067 LBO-32		
20:30 - 20:45					Pregnancy 11308 O-277	Cirrhosis 20144 LBO-19	HCV 10194 O-57	HCC 11253 O-153	HCC 20137 LBO-33		
20:50 - 21:05	*S7-7. Hepato-Renal Synd* Yogesh K. Chawla		*GS6-5 IL28* Jacob George		Pregnancy 10657 O-278		HCV 10206 O-58	HCC 10648 O-154	HCC 20017 LBO-34		
21:10 - 21:25					Pediatric 20005 LBO-21		HCV 10073 O-59	HCC 11149 O-155	ALF 20113 LBO-35		
21:30 - 21:45							HCV 10834 O-60	HCC 11126 O-156			

*The Program is subject to change.